ITM2C (integral membrane protein 2C) is a type II integral transmembrane protein that functions as a negative regulator in multiple cellular processes. The protein consists of 267-269 amino acids with an intracellular N-terminus and extracellular C-terminus, containing a conserved N-glycosylation site 1 2. ITM2C shows tissue-specific expression patterns, being highly expressed in brain tissue during both embryonic development and adulthood 1 2. The protein appears to play regulatory roles in cellular proliferation and apoptosis, as demonstrated by miR-107-5p-mediated downregulation of ITM2C promoting cell proliferation and inhibiting apoptosis in vascular smooth muscle cells 3. ITM2C has emerged as a potential biomarker in multiple disease contexts, including colorectal cancer where it shows diagnostic utility with high accuracy 4, and acute aortic dissection where reduced expression correlates with disease progression 3. In cancer biology, ITM2C functions as a hub gene regulating cellular plasticity in pediatric high-grade gliomas 5. Additionally, ITM2C is highly expressed in antibody-secreting cells and multiple myeloma cells, making it a potential therapeutic target, though knockout studies suggest it is dispensable for normal B-cell development and antibody production 6.